| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S6946 R19616 |
Palmsten (Controls exposed to TCA), 2013 | Preeclampsia and/or eclampsia (ICD-9 codes 642.4x–642.7x, after 140 gestational days and within 30 days after the delivery) | 2nd and/or 3rd trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) |
0.46 [0.33;0.64] C excluded (control group) |
183/3,517 47/441 | 230 | 3,517 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6212 R16389 |
Palmsten (Controls unexposed, sick), 2013 | Preeclampsia and/or eclampsia (ICD-9 codes 642.4x–642.7x, after 140 gestational days and within 30 days after the delivery) | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 0.99 [0.86;1.15] | 183/3,517 3,215/59,219 | 3,398 | 3,517 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5948 R15263 |
De Vera, 2012 | Pregnancy-induced hypertension (gestational hypertension, pre-eclampsia, or eclampsia after the 20th week of gestation) | during pregnancy (anytime or not specified) | nested case control | unexposed (general population or NOS) | Adjustment: Yes Matched Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 1.81 [1.02;3.23] | 18/- 1,198/- | 1,216 | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 2 studies | 1.25 [0.70;2.23] | 4,614 | 3,517 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 6946